KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Cash (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Change in Cash for 6 consecutive years, with $44.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 50.92% year-over-year to $44.8 million, compared with a TTM value of -$28.4 million through Dec 2025, down 223.3%, and an annual FY2025 reading of -$28.4 million, down 223.3% over the prior year.
  • Change in Cash was $44.8 million for Q4 2025 at AbCellera Biologics, up from -$9.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $245.8 million in Q2 2022 and bottomed at -$417.4 million in Q3 2022.
  • Average Change in Cash over 5 years is -$21.9 million, with a median of -$8.3 million recorded in 2023.
  • Peak annual rise in Change in Cash hit 341.35% in 2021, while the deepest fall reached 1146.27% in 2021.
  • Year by year, Change in Cash stood at -$16.6 million in 2021, then surged by 187.98% to $14.6 million in 2022, then tumbled by 368.51% to -$39.1 million in 2023, then skyrocketed by 175.92% to $29.7 million in 2024, then surged by 50.92% to $44.8 million in 2025.
  • Business Quant data shows Change in Cash for ABCL at $44.8 million in Q4 2025, -$9.3 million in Q3 2025, and -$66.8 million in Q2 2025.